Interchange Capital Partners LLC Lowers Stake in Gilead Sciences, Inc. $GILD

Interchange Capital Partners LLC cut its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 87.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 240 shares of the biopharmaceutical company’s stock after selling 1,648 shares during the quarter. Interchange Capital Partners LLC’s holdings in Gilead Sciences were worth $27,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. One Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 2,364 shares in the last quarter. Ariel Investments LLC boosted its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after acquiring an additional 30,630 shares during the last quarter. Golden State Wealth Management LLC boosted its position in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after acquiring an additional 109 shares during the last quarter. Covea Finance boosted its position in shares of Gilead Sciences by 69.5% in the second quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock worth $5,732,000 after acquiring an additional 21,200 shares during the last quarter. Finally, Swedbank AB boosted its position in shares of Gilead Sciences by 0.8% in the first quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock worth $237,393,000 after acquiring an additional 16,663 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 0.2%

NASDAQ GILD opened at $118.30 on Thursday. The company’s fifty day simple moving average is $115.00 and its 200-day simple moving average is $110.41. Gilead Sciences, Inc. has a 52 week low of $85.60 and a 52 week high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $146.79 billion, a P/E ratio of 23.57, a PEG ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the previous year, the company posted $2.01 earnings per share. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s payout ratio is presently 62.95%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on GILD. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Rothschild & Co Redburn raised their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Citigroup raised their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research report on Wednesday, October 8th. Finally, Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $118.08.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,000 shares of company stock valued at $7,632,100. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.